[1]STRAND V, KIMBERLY R, ISAACS J D. Biologic therapies in rheumatology: lessons learned, future directions [J]. Nature reviews Drug discovery, 2007, 6(1): 75-92.[2]孙铁铮, 吕厚山, 药立波, et al. 酪氨酸激酶在 TNF-α诱导类风湿关节炎成纤维样滑膜细胞 MAPKs 活化中的作用 [J]. 中华微生物学和免疫学杂志, 2001, 01): 74-8.[3]李俊松, 杨娉婷, 肖卫国. 肿瘤坏死因子α诱导类风湿关节炎成纤维样滑膜细胞增殖机制的研究 [J]. 中华内科杂志,2008, 47(10)：845-6.[4]罗心静, 莫选荣, 周玲玲. TNF-α诱导类风湿关节炎滑膜细胞NF-κB信号通路活化的探讨 [J]. 免疫学杂志, 2012, 04): 321-3+32.[5]STANFORD S M, ALEMAN MUENCH G R, BARTOK B, et al. TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness [J]. Annals of the rheumatic diseases, 2016, 75(1): 295-302.[6]EDHAYAN G, OHARA R A, STINSON W A, et al. Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis [J]. Arthritis research & therapy, 2016, 18(87.[7]BARTOK B, FIRESTEIN G S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis [J]. Immunological reviews, 2010, 233(1): 233-55.[8]KAWASHIRI S Y, KAWAKAMI A, IWAMOTO N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs [J]. The Journal of rheumatology, 2009, 36(11): 2397-402.[9]PAP T, AUPPERLE K R, GAY S, et al. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion [J]. Arthritis and rheumatism, 2001, 44(3): 676-81.[10]FRANZ J K, PAP T, HUMMEL K M, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis [J]. Arthritis and rheumatism, 2000, 43(3): 599-607.[11]LEE S Y, KWOK S K, SON H J, et al. IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation [J]. Arthritis research & therapy, 2013, 15(1): R31.[12]SCHEDEL J, GAY R E, KUENZLER P, et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis [J]. Arthritis and rheumatism, 2002, 46(6): 1512-8.[13]ZHOU L, LI L, WANG Y, et al. Effects of RANKL on the proliferation and apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis through regulating the NF-κB signaling pathway [J]. European review for medical and pharmacological sciences, 2019, 23(21): 9215-21.[14]TANIDA A, KISHIMOTO Y, OKANO T, et al. Etanercept Promotes Bone Formation via Suppression of Dickkopf-1 Expression in Rats with Collagen-Induced Arthritis [J]. Yonago acta medica, 2013, 56(1): 13-9.[15]CHOE J Y, HUN KIM J, PARK K Y, et al. Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor α induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis [J]. Rheumatology (Oxford, England), 2016, 55(5): 928-38.[16]OHARA R A, EDHAYAN G, RASMUSSEN S M, et al. Citrullinated Inhibitor of DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis [J]. Arthritis & rheumatology (Hoboken, NJ), 2019, 71(8): 1241-51.[17]PATTACINI L, BOIARDI L, CASALI B, et al. Differential effects of anti-TNF-alpha drugs on fibroblast-like synoviocyte apoptosis [J]. Rheumatology (Oxford, England), 2010, 49(3): 480-9.[18]LEE C K, LEE E Y, CHUNG S M, et al. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand [J]. Arthritis and rheumatism, 2004, 50(12): 3831-43.
